Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476393 | 0.92 | BDKRB1 (0.66) | BDKRB1 | |
| SCHEMBL12476815 | 0.86 | BDKRB1 (0.70) | BDKRB1 | |
| SCHEMBL2947184 | 0.84 | BDKRB1 (0.57) | BDKRB1 | |
| SCHEMBL4960208 | 0.82 | BDKRB1 (0.82) | BDKRB1 | |
| SCHEMBL3615281 | 0.81 | BDKRB1 (0.62) | BDKRB1 | |
| SCHEMBL12477012 | 0.81 | BDKRB1 (0.71) | BDKRB1 | |
| SCHEMBL13213913 | 0.81 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL5360427 | 0.81 | BDKRB1 (0.48) | BDKRB1 | |
| SCHEMBL12476392 | 0.80 | BDKRB1 (0.60) | BDKRB1 | |
| SCHEMBL3627119 | 0.79 | BDKRB1 (0.71) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893579-B1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2396301-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2011-12-21 | — | — | EP | disclosed |
| US-7816380-B2 | 1-hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| WO-2010091876-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2009-03-05 | — | — | US | disclosed |
| EP-1893579-A1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006132837-A1 | l-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, HRH4 | BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.